Trial Profile
A Randomised, Parallel-Arm, Open-Label Trial Comparing Degarelix With Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Reduction in International Prostate Symptom Score (IPSS), in Patients With Lower Urinary Tract Symptoms (LUTS) Secondary to Locally Advanced Prostate Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Degarelix (Primary) ; Bicalutamide; Goserelin
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 09 Apr 2022 This trial has been completed in Spain, according to European Clinical Trial database record.
- 15 Apr 2014 Results from a pooled analysis presented at the 29th Congress of the European Association of Urology.
- 13 Feb 2013 German Clinical Trials Register reports actual trial initiation date as 30 Apr 2009.